Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9448-9456

  Wang, Diping ^a   Montgomery, R Bruce ^b   Schmidt, Lucy J ^a   Mostaghe, Elahe A ^b,c   Huang, Haojie ^d   Nelson, Peter S ^b,c   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANDROGENS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73649131673     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1903     Document Type: Article

References (43)

1. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
2. Debes JD, Tindall DJ.Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
4. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
5. Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua R. TNF-α/IL-1/NF-κB transduction pathway in human cancer prostate. Histol Histopathol 2008;23:1279-90.
6. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
7. Mizokami A, Gotoh A, Yamada H, Keller ET,Matsumoto T. Tumor necrosis factor-α represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-5.
8. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
9. Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-α-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004;203:145-54.
10. Supakar PC, Jung MH, Song CS, Chatterjee B, Roy AK. Nuclear factor κB functions as a negative regulator for the rat androgen receptor gene and NF-κB activity increases during the age-dependent desensitization of the liver. J Biol Chem 1995;270:837-42.
11. Ko S, Shi L, Kim S, Song CS, Chatterjee B. Interplay of nuclear factor-κB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor α. Mol Endocrinol 2008;22:273-86.
12. Zhao X, van Steenbrugge GJ, Schroder FH. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 1992;20:193-7.
13. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995;81:495-504.
14. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998;12:2821-30.
15. Park YC, Ye H, Hsia C, et al. A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell 2000;101:777-87.
16. Michallet MC, Meylan E, Ermolaeva MA, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 2008;28:651-61.
17. Ermolaeva MA, Michallet MC, Papadopoulou N, et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol 2008;9:1037-46.
18. Pobezinskaya YL, Kim YS, Choksi S, et al. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat Immunol 2008;9:1047-54.
19. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-5.
20. Pritchard CC, Hsu L, Delrow J, Nelson PS. Project normal: defining normal variance in mouse gene expression. Proc Natl Acad Sci U S A 2001;98:13266-71.
21. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001;276:38830-6.
22. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674-85.
23. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991-6.
24. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
25. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
26. Horoszewicz JS, Leong SS, Chu TM, et al. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-32.
27. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
28. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
29. Nakajima Y, DelliPizzi AM, Mallouh C, Ferreri NR. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate 1996;29:296-302.
30. Natoli G, Austenaa LM. A birthday gift for TRADD. Nat Immunol 2008;9:1015-6.
31. Rokudai S, Fujita N, Kitahara O, Nakamura Y, Tsuruo T. Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol 2002;22:8695-708.
32. Ellis WJ, Vessella RL, Buhler KR, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-48.
33. Corey E, Quinn JE, Buhler KR, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46.
34. Altuwaijri S, Lin HK, Chuang KH, et al. Interruption of nuclear factor κB signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003;63:7106-12.
35. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-α and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 2006;91:546-54.
36. Nelius T, Filleur S, Yemelyanov A, et al. Androgen receptor targets NFκB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007;121:999-1008.
37. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
38. Jin F, Liu X, Zhou Z, et al. Activation of nuclear factor-κB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005;65:6354-63.
39. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-κB-dependent pathway. Endocrinology 2004;145:1889-97.
40. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(κ)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160-7.
41. Jin RJ, Lho Y, Connelly L, et al. The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008;68:6762-9.
42. Chen CD, Sawyers CL. NF-κB activates prostat-especific antigen expression and is upregulated in androgenindependent prostate cancer. Mol Cell Biol 2002;22:2862-70.
43. Cinar B, Yeung F, Konaka H, et al. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-κB signalling in prostate cancer cells. Biochem J 2004;379:421-31.